156 290

Cited 6 times in

Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma

DC FieldValueLanguage
dc.contributor.author강석구-
dc.contributor.author장종희-
dc.date.accessioned2014-12-18T10:01:13Z-
dc.date.available2014-12-18T10:01:13Z-
dc.date.issued2013-
dc.identifier.issn2005-3711-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/89264-
dc.description.abstractObjective : To evaluate the efficacy of temozolomide (TMZ) chemotherapy for recurrent anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA). Methods : A multi-center retrospective trial enrolled seventy-two patients with histologically proven AO/AOA who underwent TMZ chemotherapy for their recurrent tumors from 2006 to 2010. TMZ was administered orally (150 to 200 mg/m2/day) for 5 days per 28 days until unacceptable toxicity occurred or tumor progression was observed. Results : TMZ chemotherapy cycles administered was median 5.3 (range, 1-41). The objective response rate was 24% including 8 cases (11%) of complete response and another 23 patients (32%) were remained as stable disease. Severe side effects (≥grade 3) occurred only in 9 patients (13%). Progression-free survival (PFS) of all patients was a median 8.0 months (95% confidence interval, 6.0-10.0). The time to recurrence of a year or after was a favorable prognostic factor for PFS (p<0.05). Overall survival (OS) was apparently differed by the patient's histology, as AOA patients survived a median OS of 18.0 months while AO patients did not reach median OS at median follow-up of 11.5 months (range 2.7-65 months). Good performance status of Eastern Cooperative Oncology Group 0 and 1 showed prolonged OS (p<0.01). Conclusion : For recurrent AO/AOA after surgery followed by radiation therapy, TMZ could be recommended as a salvage therapy at the estimated efficacy equal to procarbazine, lomustine, and vincristine (PCV) chemotherapy at first relapse. For patients previously treated with PCV, TMZ is a favorable therapeutic option as 2nd line salvage chemotherapy with an acceptable toxicity rate.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfJOURNAL OF KOREAN NEUROSURGICAL SOCIETY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleTemozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Neurosurgery (신경외과학)-
dc.contributor.googleauthorGwak Ho-Shin-
dc.contributor.googleauthorYee Gi Taek-
dc.contributor.googleauthorPark Chul-Kee-
dc.contributor.googleauthorKim Jin Wook-
dc.contributor.googleauthorHong Yong-Kil-
dc.contributor.googleauthorKang Seok-Gu-
dc.contributor.googleauthorKim Jeong Hoon-
dc.contributor.googleauthorSeol Ho Jun-
dc.contributor.googleauthorJung Tae-Young-
dc.contributor.googleauthorChang Jong Hee-
dc.contributor.googleauthorYoo Heon-
dc.contributor.googleauthorHwang Jeong-Hyun-
dc.contributor.googleauthorKim Se-Hyuk-
dc.contributor.googleauthorPark Bong Jin-
dc.contributor.googleauthorHwang Sun-Chul-
dc.contributor.googleauthorKim Min Su-
dc.contributor.googleauthorKim Seon-Hwan-
dc.contributor.googleauthorKim Eun-Young-
dc.contributor.googleauthorKim Ealmaan-
dc.contributor.googleauthorKim Hae Yu-
dc.contributor.googleauthorKo Young-Cho-
dc.contributor.googleauthorYun Hwan Jung-
dc.contributor.googleauthorYoun Ji Hye-
dc.contributor.googleauthorKim Juyoung-
dc.contributor.googleauthorLee Byeongil-
dc.contributor.googleauthorLee Seung Hoon-
dc.identifier.doi10.3340/jkns.2013.54.6.489-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00036-
dc.contributor.localIdA03470-
dc.relation.journalcodeJ01520-
dc.identifier.eissn1598-7876-
dc.identifier.pmid24527191-
dc.subject.keywordAnaplastic oligoastrocytoma-
dc.subject.keywordAnaplastic oligodendroglioma-
dc.subject.keywordChemotherapy-
dc.subject.keywordRecurrence-
dc.subject.keywordTemozolomide-
dc.contributor.alternativeNameKang, Seok Gu-
dc.contributor.alternativeNameChang, Jong Hee-
dc.contributor.affiliatedAuthorKang, Seok Gu-
dc.contributor.affiliatedAuthorChang, Jong Hee-
dc.rights.accessRightsfree-
dc.citation.volume54-
dc.citation.number6-
dc.citation.startPage489-
dc.citation.endPage495-
dc.identifier.bibliographicCitationJOURNAL OF KOREAN NEUROSURGICAL SOCIETY, Vol.54(6) : 489-495, 2013-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.